Investor's Business Daily on MSN

Why former highflier Corcept Therapeutics just surged again

Corcept Therapeutics shares jumped Thursday after the company said its drug cut the risk of death by 35% in ovarian cancer ...
This important study combines a two-person joint hand-reaching paradigm with game-theoretical modeling to examine whether, and how, one's reflexive visuomotor responses are modulated by a partner's ...
Many people who use these medications don’t want to stay on them long term. But research has repeatedly shown that quitting ...
Expectant mothers face significant flu risks, with complications like pneumonia and respiratory distress being more severe ...
The Cuban government has belatedly and indirectly acknowledged that a portion of those infected with the chikungunya virus will experience chronic ...
Research led by Lancaster University has discovered that a class of antibiotics—fluoroquinolones—can directly alter the ...
Caterpillar has revamped its largest backhoes – the 440 and 450 – with new engines, hydraulics and other features. Watch at ...
Pathologic 3's time travel format might seem to diminish Pathologic's challenges, but is actually a new and diseased way of ...
Thermal analysis using DSC and QI MDSC techniques uncovers material interactions, essential for assessing pharmaceutical ...
Read our live updates from CES 2026 in Las Vegas to see the latest consumer gadgetry in all of its chatbot-enabled, ...
A first-in-human pilot trial suggests umbilical cord–derived mesenchymal stem cell eye drops may safely improve symptoms and inflammation in refractory dry eye, including Sjögren’s syndrome.
Important deadlines include February 1 and March 1, 2026, for abstract submissions, and April 12, 2026, for early-bird ...